FDA approves first anti-C1s antibody, targeting innate immunity for rare anaemia

被引：0
|
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 04期
关键词：
D O I：
10.1038/d41573-022-00049-7
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：249 / 249
页数：1
相关论文
共 50 条
  • [41] A humanized anti-b7h3x4-1BB bispecific antibody exerts potent antitumour effects through the activation of innate and adaptive immunity
    Wang, Fengrong
    Zhao, Qun
    Liu, Wenting
    Zhang, Dayan
    Dai, Xuejing
    Zhou, Weiming
    Zeng, Xiaoli
    Zhang, Yan
    Cheng, Liansheng
    Shen, Guodong
    Gu, Yanting
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2025, 749
  • [42] Selection of aptamers with high affinity and high specificity against C595, an anti-MUC1 IgG3 monoclonal antibody, for antibody targeting
    Missailidis, S
    Thomaidou, D
    Borbas, KE
    Price, MR
    JOURNAL OF IMMUNOLOGICAL METHODS, 2005, 296 (1-2) : 45 - 62
  • [43] Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 × anti-c-ErbB-2 bispecific antibody
    Yasushi Ohmi
    Hiroshi Shiku
    Takashi Nishimura
    Cancer Immunology, Immunotherapy, 1999, 48 : 456 - 462
  • [44] CLAUDIN-1 targeting antibody ALE.C04 drives single activity and restores anti-PD1 efficacy in solid tumors
    Toso, Alberto
    Teixeira, Geoffrey
    Zimmermann, Tina
    Gill, Stefanie Gill
    Schmitter, Daniela
    Meyer, Markus
    Muller, Marion
    Mailly, Laurent
    Baumert, Thomas
    Manenti, Luigi
    Iacone, Roberto
    CANCER RESEARCH, 2023, 83 (08)
  • [45] Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 x anti-c-ErbB-2 bispecific antibody
    Ohmi, Y
    Shiku, H
    Nishimura, T
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1999, 48 (08) : 456 - 462
  • [46] RETRACTED: Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity (Retracted article. See vol. 11, 2022)
    Dougall, William C.
    Aguilera, Amelia Roman
    Smyth, Mark J.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2019, 8 (10)
  • [47] RETRACTION: Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity (Retraction of Vol 8, art no E01081, 2019)
    Dougall, W. C.
    Roman, Aguilera A.
    Smyth, M. J.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2022, 11 (02)
  • [48] First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors
    Shimizu, Toshio
    Powderly, John
    Abdul Razak, Albiruni
    Lorusso, Patricia
    Miller, Kathy D.
    Kao, Steven
    Kongpachith, Sarah
    Tribouley, Catherine
    Graham, Michelle
    Stoll, Brian
    Patel, Maulik
    Sahtout, Mohammad
    Blaney, Martha
    Leibman, Rachel
    Golan, Talia
    Tolcher, Anthony
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [49] Targeting Design of Human Anti-idiotypic Genetically Engineered Antibody for Simulating the Structure and Insecticidal Function of Bt Cry1C Toxin
    Xu, Chongxin
    Shen, Jianxing
    Chen, Wei
    Sun, Xiaoming
    Zhang, Xiao
    Liu, Yuan
    Liu, Xianjin
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2024, 72 (39) : 21650 - 21666
  • [50] The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model
    Zhang, Ke
    Wuri, Qimuge
    Cai, Zongyu
    Qu, Xueli
    Zhang, Shiqi
    Wu, Hui
    Wu, Jiaxin
    Wang, Chu
    Yu, Xianghui
    Kong, Wei
    Zhang, Haihong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
12345